



Amyloid- β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease

Edmarie Guzmán-Vélez^{a,1}, Ibai Díez^{b,c,1} , Dorothee Schoemaker^a, Enmanuelle Pardilla-Delgado^{a,d} , Clara Vila-Castelar^a , Joshua T. Fox-Fuller^{a,e}, Ana Baena^f , Reisa A. Sperling^{g,h}, Keith A. Johnson^{b,g,h}, Francisco Loperaⁱ , Jorge Sepulcre^{b,c,2,3}, and Yakeel T. Quiroz^{a,c,f,g,2,3}

Edited by Daniel Geschwind, University of California Los Angeles Center for Autism Research and Treatment, Los Angeles, CA; received August 4, 2021; accepted February 28, 2022 by Editorial Board Member Michael S. Gazzaniga

The human brain is composed of functional networks that have a modular topology, where brain regions are organized into communities that form internally dense (segregated) and externally sparse (integrated) subnetworks that underlie higher-order cognitive functioning. It is hypothesized that amyloid- β and tau pathology in preclinical Alzheimer's disease (AD) spread through functional networks, disrupting neural communication that results in cognitive dysfunction. We used high-resolution (voxel-level) graph-based network analyses to test whether in vivo amyloid- β and tau burden was associated with the segregation and integration of brain functional connections, and episodic memory, in cognitively unimpaired Presenilin-1 E280A carriers who are expected to develop early-onset AD dementia in ~ 13 y on average. Compared to non-carriers, mutation carriers exhibited less functional segregation and integration in posterior default-mode network (DMN) regions, particularly the precuneus, and in the retrosplenial cortex, which has been shown to link medial temporal regions and cortical regions of the DMN. Mutation carriers also showed greater functional segregation and integration in regions connected to the salience network, including the striatum and thalamus. Greater tau burden was associated with lower segregated and integrated functional connectivity of DMN regions, particularly the precuneus and medial prefrontal cortex. In turn, greater tau pathology was related to higher segregated and integrated functional connectivity in the retrosplenial cortex and the anterior cingulate cortex, a hub of the salience network. These findings enlighten our understanding of how AD-related pathology distinctly alters the brain's functional architecture in the preclinical stage, possibly contributing to pathology propagation and ultimately resulting in dementia.

familial Alzheimer's disease | fMRI | positron emission tomography | pathology | resting-state functional connectivity

The progressive accumulation of amyloid- β plaques and neurofibrillary tangles in Alzheimer's disease (AD) begins several years before symptom onset (i.e., the preclinical stage) (1, 2) and follows distinct spatiotemporal patterns (3, 4). Amyloid- β accumulates throughout anatomically distant neocortical regions approximately two decades before the onset of memory impairment (2, 5), whereas tau accumulation is first observed in the transentorhinal and entorhinal cortex, later spreading into adjacent association and unimodal cortices (6–8). These patterns of pathology accumulation are highly reminiscent of functional brain networks, which can be represented by the interregional coherence of spontaneous neural activity fluctuations during rest using functional magnetic resonance imaging (fMRI). This has led some to hypothesize that pathology propagation in AD may occur through functional networks (9–11). In vivo neuroimaging studies have shown that amyloid- β first accumulates in a set of distributed brain regions that form part of the so-called default mode network (DMN) (i.e., precuneus, medial prefrontal and inferior parietal cortices), which is considered a backbone of mainly cortical integration (12, 13). Conversely, tau pathology begins to accumulate in vulnerable loci, later advancing to local functionally connected regions, possibly following transynaptic spread along functional connections (8, 9, 14). As such, characterizing how AD-related pathology relates to the brain's functional architecture in the preclinical stage of AD can improve our understanding of the impact of pathology on neural communication and propagation early in the disease and help with early detection, disease staging, and prediction of cognitive decline.

Some functional brain networks have been shown to undergo two distinct phases that are differentially associated with AD stages. Some studies have reported increased

SIGNIFICANCE

Amyloid- β and tau, hallmark pathologies of Alzheimer's disease (AD), are hypothesized to spread through brain functional networks that are critical for neural communication. Using high-resolution network analyses and positron emission tomography, we showed that greater tau burden was related to functional dysconnectivity of regions associated with memory function and increased connectivity of structures that are important for integrating information in cognitively unimpaired Presenilin-1 E280A carriers, who will develop early-onset AD dementia. These findings enlighten how brain pathology relates to distinct patterns of functional connectivity in regions that are essential for memory and information processing. Elucidating how brain pathology alters functional connections before individuals experience cognitive impairment could help detect AD early and predict disease progression and dementia risk.

This article is a PNAS Direct Submission. D.G. is a guest editor invited by the Editorial Board.

Copyright © 2022 the Author(s). Published by PNAS. This article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

¹E.G.-V. and I.D. contributed equally to this work.

²J.S. and Y.T.Q. contributed equally to this work.

³To whom correspondence may be addressed. Email: yquiroz@mgh.harvard.edu.

This article contains supporting information online at <http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2113641119/-/DCSupplemental>.

Published April 5, 2022.

functional connectivity (i.e., hyperconnectivity) within the DMN in cognitively unimpaired older adults with high levels of amyloid- β but low tau and reduced functional connectivity (i.e., hypoconnectivity) in those with high levels of both amyloid- β and tau (15–17). Some DMN regions, particularly the precuneus, have also been shown to act as mediators between hyperconnected and hypoconnected hubs (16), which are brain regions that are highly interconnected and that act as way stations to integrate information across different and often segregated or distributed neural systems. While some studies have suggested an inverse relationship between tau deposition and functional connectivity (16, 18), others have shown that elevated tau deposition is associated with stronger local functional connectivity early in AD (10, 19, 20). Greater functional connectivity in tau pathology hotspots have been related to a faster accumulation of tau in interconnected regions, suggesting that functional connectivity in regions that accumulate tau faster and earlier may enable the spread of tau to nearby structures that are closely functionally connected (10, 19, 21).

These complex brain networks have a modular organization—i.e., different voxels of the brain are organized in communities that specialize on distinct tasks. These modules have a large number of links that connect voxels within a community (network segregation) and a smaller set of links that integrate information between communities (network integration). However, very little is known about how early AD-related pathology—particularly tau pathology, a strong predictor of neurodegeneration and cognitive decline (22–24)—distinctly impacts the integration and segregation of networks crucial for efficient information processing. Most of the published research has been limited by focusing on amyloid- β and not tau and by studying older adults who are at high risk but may not develop AD dementia. Furthermore, many studies have examined functional connectivity by averaging sets of pair-wise correlations, thereby obscuring the intricate dynamics of functional networks and potential effects on cognitive functioning in the preclinical stage of AD.

To address these shortcomings in the field, we used high-resolution (voxel-level) graph-based network analyses to characterize the topological organization of functional connections in the brain associated with *in vivo* amyloid- β and tau burden and episodic memory in individuals with autosomal-dominant AD (ADAD) caused by the Presenilin-1 (*PSEN1*) E280A mutation. Studying ADAD provides a unique opportunity to understand the associations between AD-related pathology and functional connections in preclinical AD, as mutation carriers are virtually guaranteed to develop dementia and have limited age-related comorbidities that could contribute to brain dysfunction. *PSEN1* E280A carriers have a well-characterized clinical profile, with an onset of mild cognitive impairment (MCI) at a median age of 44 y and dementia at 49 y (25). They exhibit widespread cortical amyloid- β accumulation approximately two decades before estimated MCI onset, and tau pathology in the entorhinal cortex close to 6 y before estimated MCI onset (2, 24). They also show reduced glucose metabolism in temporal and parietal regions, including in the precuneus, more than a decade before estimated MCI onset (26).

We computed a data-driven voxel-level whole-brain analysis to create maps of functional hubs that help characterize segregated (within-network) and integrated (between-network) connections. We examined whether the segregation and integration of functional networks at resting differed between mutation carriers and age-matched noncarrier family members and their relationship to AD-related pathology burden and episodic memory. We also used a brain parcellation approach to localize

the surviving links in our results and match them to well-known canonical resting-state networks. Amyloid- β and tau burden were measured with ¹¹C Pittsburgh compound B and [¹⁸F] Flortaucipir positron emission tomography (PET), respectively. We hypothesized that there would be significant group differences in the segregation and integration of functional connections in DMN regions, particularly in the precuneus and medial temporal regions. We also hypothesized that less segregated functional connectivity would be associated with greater tau burden and worse episodic memory and stronger integrated functional connectivity with higher amyloid- β burden and worse episodic memory.

Results

Sample Characteristics. We examined 21 cognitively unimpaired *PSEN1* E280A carriers who were on average 8 y from expected symptom onset and 13 y from expected dementia onset and 31 noncarriers. The groups did not significantly differ in age, education, sex, or Mini-Mental State Examination (MMSE) scores (Table 1). Compared to noncarriers, mutation carriers performed significantly worse than noncarriers in the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) word list delayed recall, a measure of episodic memory that is sensitive to early cognitive changes in this population ($F(1, 49) = 7.87, P = 0.007, d = 0.73$) (Table 1) (25).

Segregated and Integrated Functional Connectivity Patterns Differ between Cognitively Unimpaired Mutation Carriers and Noncarriers. We first examined whether there were distinct patterns of segregated and integrated functional connectivity between groups. Higher values in segregated functional connectivity maps denote that a given voxel has a greater number of strongly functionally connected links to other regions of the same functional network, whereas higher values in integrated functional connectivity maps mean that the voxel is an important hub for integrating information between brain communities.

Compared to noncarriers, mutation carriers exhibited less functional segregation and integration of posterior DMN regions that subserve episodic memory (Fig. 1). Specifically, we observed less segregated and integrated functional connectivity in the precuneus, a hub of the DMN that is vulnerable to early tau accumulation in this cohort (24). We also found less integrated functional connectivity in the retrosplenial cortex, which has been suggested to link subcortical systems (i.e., medial temporal regions) and cortical regions of the DMN (27). This finding suggests that the precuneus is functionally disconnected from regions within network as well as other brain communities, while the retrosplenial cortex is disconnected from regions across networks.

We then conducted two seed-based post hoc analyses of the fMRI data to better characterize functional connectivity patterns of these two regions (*SI Appendix*). The precuneus seed exhibited less functional segregation with other DMN regions, including the posterior cingulate cortex, supramarginal, and temporal and medial frontal cortex. On the other hand, the retrosplenial cortex exhibited less functional integration with regions from the salience network, as well as the hippocampus and brainstem (*SI Appendix, Fig. S1*). Notably, the observed dysconnectivity of these structures with other brain regions is unlikely due to atrophy, a marker of neurodegeneration, as we did not observe significant atrophy in any of the posterior regions (*SI Appendix, Fig. S2*). This result suggests that the

Table 1. Demographic and cognitive data

Parameter	Mean (SD)		P value
	Noncarriers (n = 31)	Mutation carriers (n = 21)	
Demographics			
Age (years)	35.59 (4.75)	35.99 (5.02)	0.775
Education	11.68 (4.00)	10.19 (3.84)	0.185
Sex (% males)	48.4	47.7	0.957
Cognitive tests			
FAST (n scores 1/2)	29/4	16/5	0.072
MMSE	28.9 (0.91)	28.43 (0.98)	0.085
CERAD delayed recall	7.81 (1.28)	6.52 (2.06)	0.007

Compared to noncarriers, cognitively unimpaired mutation carriers exhibited significantly worse CERAD word list delayed recall scores. Groups did not differ between in age, education, sex, FAST or MMSE scores. FAST, Functional Assessment Staging Test; MMSE, Mini Mental State Examination; CERAD, Consortium to Establish a Registry for Alzheimer's Disease.

observed functional changes precede neurodegeneration and may instead be associated with other pathophysiological processes, such as the accumulation of tau pathology, as we report in the next section.

Mutation carriers also exhibited greater segregated and integrated functional connectivity of mostly salience network regions compared to noncarriers (Fig. 1). Specifically, we observed greater segregation in the thalamus and integration in the striatum, medial frontal cortex, and paracentral lobule. This finding suggests

that the thalamus is hyperconnected to within-network regions and the other regions to other brain communities.

Amyloid- β and tau Burden Are Distinctively Associated with Functional Connectivity Maps in Cognitively Unimpaired Mutation Carriers. We then examined the association between functional segregation and integration patterns with AD progression in the preclinical stage. Specifically, we conducted a bipartite graph analysis to elucidate the relationship between




Fig. 1. Differences in segregated and integrated network connectivity between cognitively unimpaired mutation carriers and noncarriers. Differences in functional segregation and integration between mutation carriers and noncarriers are displayed. Red-yellow colors show the trend ($Z > 1.64$; $P < 0.1$) of greater functional connectivity, while blue regions display less functional connectivity in mutation carriers compared to noncarriers. Regions with a $P < 0.05$ and surviving to multiple comparisons are indicated with black borders. The graphs at the right display the distribution of functional connectivity for the surviving clusters, with noncarriers being represented in blue and mutation carriers in red. Circles below the curves for each brain structure represent data for a single subject. L = left; R = right.

pathology burden in voxels that harbor high levels of pathology and the fMRI voxels with altered functional segregation or integration (Fig. 2A).

First, we found that the precuneus, inferior temporal, and entorhinal cortices had the greatest accumulation of tau pathology in mutation carriers compared to noncarriers (Fig. 2A), as previously reported (24). We then examined how tau burden in these regions related to segregated and integrated functional connectivity in mutation carriers. We found that greater tau burden in these brain structures was associated with less segregated and integrated functional connectivity of DMN regions (SI Appendix, Fig. S3), particularly the precuneus and medial prefrontal cortex, as well as the lateral occipital cortex (Fig. 2B). That is, greater tau burden was related to a greater disruption and reduction in connectivity of these regions within the network and across brain communities.

In turn, more tau accumulation was associated with greater segregated and integrated functional connectivity in the retrosplenial cortex and integrated functional connectivity in the anterior cingulate cortex (ACC), a hub of the salience network (Fig. 2B). This finding suggests that, as tau accumulates, the retrosplenial cortex becomes highly connected to regions within network and across brain communities, while the ACC

becomes more functionally connected to regions within network only.

We then proceeded to examine the relationship between the functional segregation and integration of each of these regions (i.e., precuneus, medial prefrontal cortex, lateral occipital cortex, retrosplenial cortex, and the ACC), with amyloid- β and tau pathology. Because amyloid- β pathology accumulates in the cortex more than a decade before tau does on this kindred, looking at the relationship between amyloid- β and tau with the functional segregation and integration of these regions may provide insight into how functional connections change with disease progression. Results suggest that there is greater functional segregation and integration of the retrosplenial cortex and integration of the ACC in the presence of tau pathology compared to amyloid- β burden (Fig. 2B), while the opposite is true for the segregation and integration of DMN regions.

Functional Connectivity Alterations Are Associated with Worse Episodic Memory in Cognitively Unimpaired Mutation Carriers. Finally, we investigated whether functional brain maps were related to the CERAD word list delayed recall scores in mutation carriers. We found that higher delayed recall scores were significantly associated with higher segregated functional




Fig. 2. Relationship of segregated and integrated network connectivity, with amyloid- β and tau pathology in mutation carriers. We used a bipartite graph theory approach to investigate the association between whole-brain PET imaging and resting-state fMRI in mutation carriers. The *Top* section of A illustrates the accumulation of amyloid- β and tau pathology in different brain regions that have been used to track disease progression in mutation carriers, together with a brain representation of the brain regions that exhibit tau accumulation the earliest in mutation carriers. The *Bottom* part of A shows the bipartite graph approach that we employed on this study to test the relationship between tau burden and functional connectivity patterns. Specifically, we examined the association between voxel clusters with high tau burden and the fMRI voxels with altered functional segregation or integration. (B) The *Left* exhibits brain regions with greater tau burden in mutation carriers compared to noncarriers, shown in green. (B) Shows fMRI voxels associated with greater tau burden that survived multiple comparisons for functional segregation and integration. Red-yellow colors represent greater functional connectivity, while blue regions represent less functional connectivity. Graphs at the *Bottom* of B illustrate the correlation of amyloid- β and tau pathology in regions that are most vulnerable to early pathology accumulation with brain regions that exhibited less or greater segregation or integration. amyl, amyloid- β ; enth, entorhinal cortex; fc, functional connectivity; ITC, inferior temporal cortex; LatOccipital, lateral occipital cortex; MPFC, medial prefrontal cortex; prec, precuneus; str, striatum.

connectivity in the left middle frontal gyrus and lower functional connectivity in subcortical regions (Fig. 3). We also observed that higher delayed recall scores were related to lower integrated functional connectivity in the precuneus and medial prefrontal cortex and with greater integrated functional connectivity in the precentral cortex. We then examined whether functional connectivity mediated the relationship between pathology and delayed recall scores or whether pathology mediated the relationship between functional connectivity and delayed recall scores. We did not find a relationship, as none of the regions survived correction for multiple comparisons.

Discussion

We provide *in vivo* evidence that amyloid- β and tau pathologies relate to distinct patterns of functional segregation and integration that resemble the patterns of pathology accumulation in AD and relate to episodic memory in preclinical ADAD. We found that posterior DMN regions, particularly the precuneus, one of the earliest sites of pathology accumulation in ADAD, and the retrosplenial cortex exhibited significantly less functional segregation and integration of networks compared to age-matched noncarriers. This decrease in functional segregation and integration of the precuneus with other regions within network and across brain communities were also strongly associated with greater tau burden in the entorhinal cortex, precuneus, and inferior temporal gyrus and less to amyloid- β , suggesting that dysconnectivity of the precuneus occurs closer to symptom onset and may play a pivotal role in predicting disease progression early. Similarly, the medial prefrontal cortex, which is part of the DMN, exhibited less

segregated and integrated functional connectivity in relation to greater tau burden in the same regions.

Both the precuneus and medial prefrontal cortex are core hubs of the DMN and support complex cognition and behaviors such as episodic memory (28–30). Prior studies have suggested that individuals at high risk for AD exhibit hyperconnectivity in the DMN, before a reduction in functional connectivity is observed (15). In fact, we previously reported that children ages 9 to 17 who carry the E280A mutation exhibited increased functional connectivity of DMN regions compared to age-matched noncarriers (31). This hyperconnectivity phase has been most strongly associated with amyloid- β pathology and the hypoconnectivity phase most strongly related to tau pathology burden (15). Prior studies with other ADAD mutations have also reported decreased functional DMN segregation as individuals approach symptom onset. One particular study demonstrated decreased functional connectivity of the precuneus and other posterior DMN regions in cognitively unimpaired mutation carriers (32), while another showed that both anterior and posterior regions of the network are disrupted early (33). Notably, other studies have only observed less functional connectivity, including in the DMN and between networks, in cognitively impaired mutation carriers as measured by a score of 1 on the clinical dementia rating (CDR) scale, and not in cognitively unimpaired mutation carriers (CDR = 0) (11, 13). These studies measured functional connectivity by either calculating a global resting-state functional connectivity signature (11) or composite scores comprised of regions chosen a priori (13). These findings suggest that the voxel-wise connectivity analyses conducted in this study provide high-resolution connectome information that increases the sensitivity to detect




Fig. 3. Association between segregated and integrated network connectivity, and word list delayed recall in mutation carriers. We conducted a general linear model to evaluate the functional connectivity patterns associated with word list delayed recall scores in mutation carriers. Regions that were associated but did not survive multiple comparisons ($Z > 1.64$; $P < 0.1$) are displayed on the brain, with black borders indicating regions that survived multiple comparisons ($P < 0.05$). Red-yellow colors illustrate an association between better delayed recall scores and greater functional connectivity, and blue colors illustrate a relationship between better delayed recall scores and less functional connectivity. Scatterplots illustrate the relationship of word list delayed recall scores with functional connectivity in regions that survived multiple comparisons. MPFC, medial prefrontal cortex.

subtle disease-related changes that occur in the preclinical stage of AD.

Similar to the DMN, the salience network has also been shown to undergo a phase of hyperconnectivity associated with mostly amyloid- β , followed by hypoconnectivity (15). Consistent with these findings, mutation carriers exhibited greater segregated functional connectivity in regions connected to the salience network such as the thalamus and greater functional integration in the striatum. Similarly, greater tau burden was related to greater functional integration of the ACC, a salience network hub. While some studies have not observed changes in the salience network in preclinical AD, others have suggested that the salience network becomes disrupted early in ADAD (33) and that it is particularly vulnerable to early AD-related changes together with the DMN. Our findings suggest that some salience network regions (ACC and striatum) are hyperconnected to other brain communities in the preclinical stage of AD and others (thalamus) to within network. It is possible that the observed segregated hyperconnectivity serves as a predictor for future pathology accumulation, as animal studies have demonstrated that neuron-to-neuron propagation of tau pathology is facilitated by greater synaptic connectivity and neuronal activity (21, 34). The same can be said for the retrosplenial cortex, which is strongly connected to medial temporal regions that subserve episodic memory. Perhaps these connections will weaken with time, when tau aggregates in these regions as most of them are primarily affected by amyloid- β at this stage.

In regard to the relationship between functional connectivity and episodic memory, we observed that less integrated functional connectivity in the precuneus and medial prefrontal cortex was associated with better memory test scores. That is, mutation carriers with better episodic memory exhibited hypoconnectivity of these two DMN regions when integrating information with other networks of the brain. We also found a significant relationship between greater functional integrity in the left middle frontal gyrus and better episodic memory. While these findings may appear to conflict with the observed patterns in functional connectivity associated with pathology at a first glance, prior research suggests that hyperconnectivity in the left frontal cortex may represent a compensatory mechanism or form of neural reserve. Specifically, in a study examining individuals with ADAD and sporadic AD researchers reported that greater functional connectivity in the left frontal cortex was associated with less cognitive decline and global cognition, as well as a diminished effect of tau on cognitive performance in the presence of greater left frontal cortex connectivity in the early stages of AD (35). As such, we hypothesize that the observed hyperconnectivity of the left frontal cortex associated with better episodic memory may reflect a form of compensation or neural reserve in the preclinical stage of AD.

Altogether, our findings suggest that in the presence of tau pathology, mutation carriers exhibit largely dysconnectivity of DMN brain regions, particularly posterior regions, and increased connectivity of structures that are associated with the salience network and others that are critical for integrating information across neural systems. Based on data that have been reported and our own findings, one could hypothesize that elevated amyloid- β levels contribute to an increase in functional connectivity or neuronal firing between the precuneus and other DMN regions, and later for salience networks regions, increasing the vulnerability of these regions for early tau deposition in ADAD, and later becoming disconnected in the presence of tau pathology, further contributing to cognitive

decline. Studying the relationship between AD-related pathology and the functional organization of the brain in younger mutation carriers, as well as longitudinally, may provide the opportunity to test the aforementioned hypothesis.

The current study has multiple strengths. First, we did not rely on presenting symptoms or predicted risk (e.g., based on amyloid- β PET levels or APOE genotype) to infer whether individuals will develop dementia. Instead, we tested our hypotheses with individuals who have a well-characterized disease and clinical trajectory. In addition, we examined *in vivo* amyloid- β and tau pathology using PET imaging, which is considered the gold standard for quantifying and mapping brain pathology in AD. Mutation carriers were also young and otherwise generally healthy, which minimizes potential age-related confounding variables that contribute to brain dysfunction and cognitive decline (e.g., cardiovascular disease). Furthermore, we conducted voxel-level connectivity analyses, which provide high-resolution connectome information that increases the sensitivity to detect subtle disease-related changes that occur in the preclinical stage of AD. However, we also used a parcellation scheme to localize the surviving links in our analyses and match them to 7 well-known canonical resting-state networks. Finally, the very homogeneous clinical profile of mutation carriers allowed us to infer how functional connections may change as the disease progresses.

The present study also has caveats that must be considered when interpreting the data. First, our sample size is relatively small compared to other studies of AD. However, individuals with these mutations are relatively rare and all our participants carry a single mutation, which makes our sample highly homogeneous compared to other cohorts, and one of the largest single mutation ADAD samples with PET imaging and fMRI. Nonetheless, our findings should be validated on larger ADAD samples in the future. Furthermore, more research is needed to examine whether our findings in ADAD generalize to preclinical late-onset AD, as well as whether other genetic risk factors known to be important may impact the results in this kindred. We are currently conducting a longitudinal biomarker study with this cohort, which will provide greater insight into how an annual change in functional connectivity relates to *in vivo* pathology burden and cognitive decline over time.

Altogether, these findings highlight the importance of not limiting analyses to examining group averages or specific seeds, as they can obscure the unique and often subtle patterns of functional disintegration associated with disease progression. Our data also underscore that more attention must be given to the precuneus as an early marker of AD and key player in functional dysconnectivity. Our findings enlighten our understanding of how AD-related pathology may distinctly alter the functional architecture of the brain to interfere with the integration of information within and across different neural systems and possibly propagate the spread of pathology, ultimately resulting in cognitive impairment and dementia.

Materials and Methods

Study Design and Participants. *PSEN1* E280A carriers and age- and education-matched noncarriers from the Massachusetts General Hospital COLBOS (Colombia-Boston) longitudinal biomarker study participated in this study. Exclusion criteria included a history of psychiatric disorders, illiteracy, stroke, epilepsy, traumatic brain injury, kidney failure, human immunodeficiency syndrome, or substance abuse. To be included in this study, participants had to demonstrate no cognitive impairment on a standard cognitive battery, including a clinical diagnostic rating scale (CDR) score of 0, a Functional Assessment

Staging Test (FAST) score of 2 or less, and an MMSE score of 26 or greater. Demographic information is presented in Table 1.

The study was approved by both the institutional ethics review boards of the University of Antioquia in Colombia and Massachusetts General Hospital in Boston. Participants provided signed informed consent before participating in any procedures.

All participants in this study traveled from Colombia to Boston (USA) and underwent PET imaging and MRI at the Massachusetts General Hospital. Participants and investigators were blind to the genetic status of the individuals.

Genotyping. Genomic DNA was extracted from blood using standard protocols. *PSEN1* E280A characterization was done at the University of Antioquia as previously described (36). Genomic DNA was amplified with the primers PSEN1-S 5'-AACAGCT-CAGGAGAGGAATG-3' and PSEN1-AS 5'-GATGAGACAAGTNCCTGAA-3'. We used the restriction enzyme BsmI for restriction fragment length polymorphism analysis. Each participant was classified as a *PSEN1* E280A carrier or noncarrier.

Neuropsychological Measures. A Spanish version of the CERAD word list learning test that is sensitive to early episodic memory changes in mutation carriers was used in this study (37). On this test, participants were required to learn 10 items over 3 trials. Participants were then asked to recall as many words as they could from the previously learned list after a 10-min delay (delayed recall score). Higher scores on the delayed recall represent better performance on the memory task.

MRI and PET Data Acquisition and Preprocessing. See *SI Appendix* for acquisition and preprocessing procedures for MRI and ¹¹C Pittsburgh compound B and [¹⁸F] Flortaucipir PET.

Integration and Segregation Analysis. The human brain exhibits a modular organization where different subsets of voxels form communities with specialized tasks (38). Based on this modular organization, the brain's functional connectivity can be separated in 1) segregated links connecting all the voxels belonging to the same community and 2) integrated links connecting links of each voxel with the rest of the communities of the brain for higher cognitive integration.

A whole-brain functional connectivity matrix was computed using the Pearson *r* correlation coefficient in the time series of each pair of voxels. A 49,314 × 49,314 association matrix was obtained for each participant, and negative values were removed (14, 16). The 49,314 gray matter voxels included cortical, subcortical, brainstem, and cerebellum regions. We generated a whole brain seven resting-state network parcellation to classify each link in the connectivity matrix as segregation or integration. The seven resting-state networks of the Yeo parcellation were used as the initial seed to extend these networks to also cover subcortical, brainstem, and cerebellar regions (39).

We generated a parcellation scheme taking advantage of the same acquisition scanner and sequences offered by our local database Brain Genomics Superstruct Project Open Access (GSP) (40) based on a sample of 100 participants. Individual-subject seed connectivity was computed for visual, sensory-motor, dorsal attention (lateral-visual), ventral attention (salience), limbic, frontoparietal, and DMNs. The average population map of each network was calculated, and each voxel of the atlas was assigned to each network based on the maximum probability of each voxel belonging to each of the networks (*SI Appendix*, Fig. S4). If the link's start and end voxels belonged to the same resting state network, the link was then classified as a segregated link; otherwise, the link was classified as an integrated link. For each participant, we computed the weighted degree of segregated and integrated links separately obtaining two brain maps, namely, one for each connectivity type (41). The weighted degree represents the strength of connections that each voxel in the brain has. Higher values in the segregated map means that a given voxel has a high number of strong connecting links to other regions of the same functional network. On the other hand, high values in the integrated map mean that this voxel is an important hub for integration of information between brain communities.

Statistical Analyses

Demographics and cognition. We conducted independent samples *t* tests using SPSS Statistics, version 24.0 (IBM Corp.) to examine group differences in demographic and cognitive variables. We used the χ^2 test to examine sex and

FAST differences between groups. Analyses used a family-wise significance threshold of $P < 0.05$ to correct for multiple comparisons and Cohen's *d* to calculate effect sizes.

Segregation and integration group differences. We used a general linear model to compute a two-sample *t* test to compare segregation and integration weighted degree maps between the mutation carriers and the noncarriers, covarying for motion (MATLAB V9.6; The MathWorks, Inc.). Whole-brain correction for multiple comparisons was applied using Monte Carlo simulation with 10,000 iterations to estimate the probability of false-positive clusters with a two-tailed $P < 0.05$ (3dClustSim, <https://afni.nimh.nih.gov>).

Association between resting-state fMRI and PET images. We used a bipartite graph approach to examine the association between amyloid- β and tau burden and functional segregation and integration in mutation carriers (Fig. 2). Since the bipartite graph approach is computationally complex, we downsampled PET and fMRI segregation and integration maps to 6 mm (6,779 voxels). We employed a linear general model, adjusting for motion in fMRI, to measure the relationship between PET burden in a specific voxel and the segregation and integration in another voxel, for each pair of PET and fMRI voxels. We obtained four different association matrices, as follows: 1) relationship of tau with functional segregation, 2) relationship of tau with functional integration, 3) relationship of amyloid- β with functional segregation, and 4) relationship of amyloid- β with functional integration. We then adapted the cluster-level Monte Carlo multiple comparison correction technique to bipartite networks to control for type I errors of bipartite graphs at the link level. Only clusters of PET voxels (group of contiguous voxels with significant association) that connected to a cluster of fMRI voxels with a minimum size survived multiple comparison. To estimate the minimum size of a PET cluster and fMRI cluster to be significant with a $P < 0.05$ we generated 10,000 bipartite random networks with the same smoothing properties. We computed the likelihood of significant cluster sizes due to chance in the generated random network and only those with a $P < 0.05$ were reported. The endpoints of the links that survived multiple comparisons are displayed in both the PET and fMRI modality in Fig. 2.

Functional integration and segregation association with episodic memory. We conducted a general linear model to examine the relationship between weighted degree maps in mutation carriers and the CERAD word list delayed recall, covarying for motion (MATLAB V9.6; The MathWorks, Inc.). A whole-brain correction for multiple comparisons was applied using Monte Carlo simulation with 10,000 iterations to estimate the probability of false-positive clusters with a two-tailed $P < 0.05$ (3dClustSim, <https://afni.nimh.nih.gov>).

Data Availability. The data that support the findings of this study are available on request from the corresponding author Y.T.Q. The data are not publicly available because they contain information that could compromise research participant privacy and anonymity. All codes related to imaging analysis are available for the research community upon request for the purpose of scientific investigation, teaching or the planning of clinical research studies.

ACKNOWLEDGMENTS. We thank the Colombian families for contributing their valuable time and effort, without which this study would not have been possible. We also thank Francisco Piedrahita, Alex Navarro, Yamile Bocanegra, and Claudia Ramos from Grupo de Neurociencias, Universidad de Antioquia in Medellín, Colombia, as well as Heirangi Torrico-Teave, Arabiye Artola, Jairo Martínez, and Diana Munera from the Massachusetts General Hospital in Boston, MA, for helping coordinate visits to Boston and assisting with data collection and processing. E.G.-V. was supported by the National Institutes of Health (NIH) National Institute on Aging (NIA) (K23AG061276). Y.T.Q. was supported by the NIH NIA (R01 AG054671). J.T.F.-F. reports National Research Service Award (NRSA) support from the NIH NIA (F31AG06215801A1). C.V.-C. was supported by a grant from the Alzheimer's Association (2019A005859). E.P.-D. was supported by the National Heart, Lung, and Blood Institute (NHLBI; 3T32HL007901-19S1). J.S. was supported by grants from the NIH (R01 AG061811, R01 AG061445). D.S. received postdoctoral fellowships from the American Heart Association (20POST35110047) and the Fonds de recherche du Québec - Santé (254389).

Author affiliations: ^aDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114; ^bGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114; ^cAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown,

MA 02129; ^dDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; ^eDepartment of Psychological and Brain Sciences, Boston University, Boston, MA 02215; ^fGrupo de Neurociencias, Universidad de Antioquia, 050010 Medellín, Antioquia, Colombia; ^gDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114; and ^hCenter for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115

Author contributions: E.G.-V., I.D., R.A.S., K.A.J., F.L., J.S., and Y.T.Q. designed research; F.L., J.S., and Y.T.Q. supervised the project; E.G.-V., D.S., E.P.-D., C.V.-C., J.T.F.-F., A.B., and Y.T.Q. performed research; E.G.-V. and I.D. analyzed data; E.G.-V. and I.D. wrote the manuscript with input from all authors; and D.S., E.P.-D., C.V.-C., J.T.F.-F., A.B., R.A.S., K.A.J., F.L., J.S., and Y.T.Q. revised the manuscript critically for important intellectual content.

1. R. A. Sperling *et al.*, Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* **7**, 280–292 (2011).
2. Y. T. Quiroz *et al.*, Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. *JAMA Neurol.* **75**, 548–556 (2018).
3. C. R. Jack Jr. *et al.*, Longitudinal tau PET in ageing and Alzheimer's disease. *Brain* **141**, 1517–1528 (2018).
4. H. Braak, E. Braak, Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol. Aging* **16**, 271–278, discussion 278–284 (1995).
5. M. J. Grothe *et al.*; Alzheimer's Disease Neuroimaging Initiative, In vivo staging of regional amyloid deposition. *Neurology* **89**, 2031–2038 (2017).
6. S. K. Kaufman, K. Del Tredici, T. L. Thomas, H. Braak, M. I. Diamond, Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART. *Acta Neuropathol.* **136**, 57–67 (2018).
7. H. Braak, D. R. Thal, E. Ghebremedhin, K. Del Tredici, Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. *J. Neuropathol. Exp. Neurol.* **70**, 960–969 (2011).
8. T. Vogels *et al.*, Propagation of tau pathology: Integrating insights from postmortem and in vivo studies. *Biol. Psychiatry* **87**, 808–818 (2019).
9. L. Iaccarino *et al.*, Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's disease. *Neuroimage Clin.* **17**, 452–464 (2017).
10. N. Franzmeier *et al.*; Alzheimer's Disease Neuroimaging Initiative (ADNI), Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. *Nat. Commun.* **11**, 347 (2020).
11. R. X. Smith *et al.*, Resting-state functional connectivity disruption as a pathological biomarker in autosomal dominant Alzheimer disease. *Brain Connect.* **11**, 239–249 (2021).
12. R. F. Buckley *et al.*, Functional network integrity presages cognitive decline in preclinical Alzheimer disease. *Neurology* **89**, 29–37 (2017).
13. J. B. Thomas *et al.*, Functional connectivity in autosomal dominant and late-onset Alzheimer disease. *JAMA Neurol.* **71**, 1111–1122 (2014).
14. J. Sepulcre *et al.*, Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. *Nat. Med.* **24**, 1910–1918 (2018).
15. A. P. Schultz *et al.*, Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and tau in clinically normal individuals. *J. Neurosci.* **37**, 4323–4331 (2017).
16. J. Sepulcre *et al.*, Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain. *Alzheimers Dement.* **13**, 1261–1269 (2017).
17. C. A. Fredericks *et al.*, Early affective changes and increased connectivity in preclinical Alzheimer's disease. *Alzheimers Dement. (Amst.)* **10**, 471–479 (2018).
18. D. Berron, D. van Westen, R. Ossenkoppele, O. Strandberg, O. Hansson, Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. *Brain* **143**, 1233–1248 (2020).
19. N. Franzmeier *et al.*; Alzheimer's Disease Neuroimaging Initiative, Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease. *Brain* **142**, 1093–1107 (2019).
20. T. M. Harrison *et al.*, Tau deposition is associated with functional isolation of the hippocampus in aging. *Nat. Commun.* **10**, 4900 (2019).
21. J. W. Vogel *et al.*; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFinder Study, Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. *Nat. Commun.* **11**, 2612 (2020).
22. B. J. Hanseeuw *et al.*, Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study. *JAMA Neurol.* **76**, 915–924 (2019).
23. C. M. Huber, C. Yee, T. May, A. Dhanala, C. S. Mitchell, Cognitive decline in preclinical Alzheimer's disease: Amyloid-beta versus tauopathy. *J. Alzheimers Dis.* **61**, 265–281 (2018).
24. J. S. Sanchez *et al.*, Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: Findings from the Colombia-Boston (COLBOS) biomarker study. *Alzheimers Res. Ther.* **13**, 27 (2021).
25. N. Acosta-Baena *et al.*, Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: A retrospective cohort study. *Lancet Neurol.* **10**, 213–220 (2011).
26. A. Fleisher *et al.*, P4-068: Pre-symptomatic functional brain changes in PS1 E280A mutation carriers compared with other biomarkers: Pilot data from the Alzheimer's prevention initiative biomarker project. *Alzheimers Dement.* **9**, P729 (2013).
27. N. Kaboodvand, L. Bäckman, L. Nyberg, A. Salami, The retrosplenial cortex: A memory gateway between the cortical default mode network and the medial temporal lobe. *Hum. Brain Mapp.* **39**, 2020–2034 (2018).
28. S. Zhang, C.-S. R. Li, Functional connectivity mapping of the human precuneus by resting state fMRI. *Neuroimage* **59**, 3548–3562 (2012).
29. A. V. Utevsky, D. V. Smith, S. A. Huettel, Precuneus is a functional core of the default-mode network. *J. Neurosci.* **34**, 932–940 (2014).
30. R. A. Cooper, M. Ritchey, Cortico-hippocampal network connections support the multidimensional quality of episodic memory. *eLife* **8**, e45591 (2019).
31. Y. T. Quiroz *et al.*, Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: A cross-sectional study. *JAMA Neurol.* **72**, 912–919 (2015).
32. J. P. Chhatwal *et al.*, Impaired default network functional connectivity in autosomal dominant Alzheimer disease. *Neurology* **81**, 736–744 (2013).
33. J. P. Chhatwal *et al.*; Dominantly Inherited Alzheimer Network, Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. *Brain* **141**, 1486–1500 (2018).
34. S. Calafate *et al.*, Synaptic contacts enhance cell-to-cell tau pathology propagation. *Cell Rep.* **11**, 1176–1183 (2015).
35. N. Franzmeier *et al.*, Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. *Brain* **141**, 1186–1200 (2018).
36. C. L. Lendon *et al.*, E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. *Hum. Mutat.* **10**, 186–195 (1997).
37. D. C. Aguirre-Acevedo *et al.*, Validity and reliability of the CERAD-Col neuropsychological battery [Article in Spanish]. *Rev. Neurol.* **45**, 655–660 (2007).
38. I. Diez *et al.*, A novel brain partition highlights the modular skeleton shared by structure and function. *Sci. Rep.* **5**, 10532 (2015).
39. B. T. Yeo *et al.*, The organization of the human cerebral cortex estimated by intrinsic functional connectivity. *J. Neurophysiol.* **106**, 1125–1165 (2011).
40. A. J. Holmes *et al.*, Brain Genomics Superstruct Project initial data release with structural, functional, and behavioral measures. *Sci. Data* **2**, 150031 (2015).
41. P. Bonifazi *et al.*, Structure-function multi-scale connectomics reveals a major role of the fronto-striato-thalamic circuit in brain aging. *Hum. Brain Mapp.* **39**, 4663–4677 (2018).

Competing interest statement: The authors declare a competing interest. F.L. was supported by an Anonymous Foundation and the Administrative Department of Science, Technology and Innovation. He is the coprincipal investigator of the Alzheimer's Prevention Initiative (API) Autosomal Dominant AD Trial, which is supported by National Institute on Aging (NIA), philanthropy, Genentech, and Roche. R.A.S. receives research support from Eli Lilly (clinical trial) and the Alzheimer's Association. She is a site principal investigator or coinvestigator for Avid, Bristol-Myers Squibb, Pfizer, and Janssen Alzheimer Immunotherapy clinical trials. She receives travel funding and honoraria from AC Immune, Janssen, and Roche. She consults for Biogen, Roche, AC Immune, Eisai, Takeda, Neurocentria, and Janssen. Spouse consults for Novartis, AC Immune, and Janssen. K.A.J. has provided consulting services for Novartis, Biogen, and Eli Lilly, received support from a joint NIH-Lilly-sponsored clinical trial (A4 Study - U19AG10483), and the Alzheimer Association and Marr Foundation.